Quantum X Labs Inc. (Nasdaq: QXL) announced it has completed a demonstration of an end-to-end clinical data analysis workflow using a quantum computer simulator, according to a press release issued July 29, 2026.

The demonstration processed real clinical data through an integrated workflow that included data preparation, quantum-enabled analysis, and generation of biologically interpretable results. The workflow ran on Quantum X's quantum simulation environment, which is designed to emulate quantum computational processes.

The company's proprietary algorithm platform, operated through its subsidiary CliniQuantum, is designed to enable quantum-enhanced sampling for continuous probability distributions used in statistical analyses of clinical trial and biomedical datasets. The platform is supported by the company's intellectual property portfolio and patent filings.

"This milestone demonstrates that our platform is not conceptual, it is operational," said Dr. Tidhar Turgeman, head of clinical trials data analysis at Quantum X. "We have shown that clinical data can be processed end to end within our system, enabling quantum enabled analytics while preserving the ability to interpret results in a meaningful scientific context."

Quantum X said it plans to expand the scale of supported datasets, optimize its quantum algorithms, and conduct performance studies on the value of quantum computing for clinical research, clinical trial analytics, and precision medicine applications.

Quantum X Labs and its subsidiaries operate across quantum technology, digital advertising, computing, and enterprise artificial intelligence solutions.